Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by the presence of numerous inflammatory mediators and the destruction of diarthrodial joints. GM-CSF was initially discovered for its role in the differentiation of hemopoietic precursor cells into mature granulocytes and macrophages [1] ; however, it can also affect
Results

GM-CSF blockade prior to onset of arthritis results in less severe disease
Mice were treated i.p. with increasing doses of anti-GM-CSF (30, 100, and 300 µg) beginning at day 21, and then every second day until day 31. Control mice received the highest dose (300 µg) of control mAb. There was a doserelated suppression of the clinical score, with mice receiving 300 µg anti-GM-CSF mAb showing a marked reduction of disease (Fig. 1a) . This decrease in severity was seen both as a reduction in the number of affected limbs per mouse and as lower clinical scores for these affected limbs (see Supplementary Fig. 1 ). However, while there was a trend towards a lower incidence of arthritis with increasing doses of anti-GM-CSF mAb, this did not reach significance (Fig. 1b) .
Decreasing the number of treatments resulted in a reduced effect on disease outcome (see Supplementary Fig. 2a ).
Anti-GM-CSF mAb treatment before the booster injection (day 21), when the CII-specific immune response was developing, had no significant effect on disease (see Supplementary Fig. 2b,c) . 
GM-CSF blockade prevents the clinical progression of established arthritis
After observing that anti-GM-CSF could be beneficial when given appropriately prior to the onset of clinical arthritis, its therapeutic effect was sought by beginning treatment after the onset of clinical arthritis. Once mice had clinical signs of inflammation they were paired according to their arthritic score and assigned to either the anti-GM-CSF mAb or control mAb treatment group. Mice were treated i.p. daily (300 µg) from the day of disease onset (day 0) to day 9 after onset (i.e. a total of 10 times).
Mice injected with anti-GM-CSF mAb showed no major progression of disease, with the mean clinical score not significantly different on day 10 compared with day 0 (disease onset) (2.8 ± 0.4 versus 1.9 ± 0.2, respectively; P > 0.05) (Fig. 2) . Control mAb-treated mice, in contrast, showed typical disease progression with a significantly higher mean clinical score on day 10 compared with day 0 (5.4 ± 0.7 versus 1.9 ± 0.2, respectively; P = 0.0001) (Fig. 2) . Anti-GM-CSF mAb-treated mice thus developed significantly milder disease than control mAb-treated mice (day 10, 2.8 ± 0.4 versus 5.4 ± 0.7; P = 0.007). There was no increase in the severity of arthritis following cessation of treatment with either mAb (day 10) (Fig. 2 ).
This absence of disease progression was seen as a relative lack of an increase in the clinical score of initially affected limbs following anti-GM-CSF treatment. Furthermore, anti-GM-CSF-treated mice showed a diminished recruitment of additional limbs that were normal at the commencement of treatment (see Supplementary Fig. 3 ).
Reduced histopathology of joints following GM-CSF blockade
Both inflammation and joint destruction are aspects of arthritis, and while treatment may alleviate one aspect (e.g. inflammation) it may have no effect on another (e.g. joint destruction) [12] . The histologic features of infiltration, cartilage damage, proteoglycan depletion and bone erosions were lower in anti-GM-CSF mAb-treated mice compared with control mAb-treated mice (P < 0.0001, two-way analysis of variance; data not shown). The mean total score for the anti-GM-CSF mAb-treated group was significantly lower than for control mAb-treated mice when the histologic scores for each feature were combined for each treatment group (3.7 ± 0.5 versus 5.9 ± 0.8; P = 0.03). Figure 3 shows a normal joint and representative joints from arthritic mice following treatment with either control mAb or anti-GM-CSF mAb. There is less cellular infiltration and cartilage destruction in the anti-GM-CSF mAb-treated mouse compared with the control-treated mouse, in parallel with the reduction in clinical score.
Humoral and cellular response to CII following GM-CSF blockade in vivo
CIA development is dependent on a B-cell and T-cell response [10, 15] , and GM-CSF is implicated in the development of antigen presenting cells [16] . Treatment with anti-GM-CSF mAb had no effect on the anti-CII IgG response, nor the proliferative response of T cells to CII (see Supplementary Fig. 4 ).
Reduced cytokine levels in joint tissues following GM-CSF blockade in vivo
GM-CSF was only detectable in the joint washouts of mice with arthritis. Levels tended to be lower in anti-GM-CSF mAb-treated mice than control mAb-treated mice (Fig. 4) .
There was also a significant reduction in the mean levels of both TNFα and IL-1β in the joint washouts for anti-GM-CSF mAb-treated mice compared with control mAb-treated mice (P = 0.02 and P = 0.007, respectively) (Fig. 4) .
None of the cytokines could be detected in the serum of any of the mice at any time point measured for the various treatment regimes (data not shown).
Discussion
There is mounting evidence for a role of GM-CSF in inflammatory disease, including arthritis. In the present study, we confirm the essential role of GM-CSF in ongoing development of inflammation and arthritis in CIA using a neutralizing mAb that blocks GM-CSF. We show that it is not only possible to ameliorate arthritis when treated prior to onset of clinical disease at the time of antigen challenge but, importantly, arthritis is also reduced in mice with established disease. Treatment of established disease is what is required of a therapeutic agent for RA. We have previously shown that injection of GM-CSF exacerbates CIA [8] , while GM-CSF gene-deficient mice are essentially resistant to CIA [9] .
The apparent importance of timing for the effectiveness of anti-GM-CSF mAb treatment provides insight into the role that GM-CSF might play in the pathogenesis of arthritis. The fact that the antibody and cellular proliferative responses to CII were not reduced by anti-GM-CSF administration, and the lack of evidence so far for subsequent disease suppression if administered prior to antigen challenge, at least with the protocols tried, suggest that GM-CSF is involved in later events associated with the effector phase. Such events are subsequent to T-cell activation, and most probably effect mediators of inflammation (e.g. cytokines).
In keeping with the decrease in disease severity following anti-GM-CSF mAb treatment, we found the mean levels of TNFα and IL-1β were reduced in ankle joint washouts of anti-GM-CSF mAb-treated mice. These reduced levels correlated with disease severity and suggest that GM-CSF plays an important role in the local expression of the Effect of anti-GM-CSF treatment on cytokine levels in the joints. GM-CSF, TNFα and IL-1β levels were measured by enzyme-linked immunosorbent assay in washouts from ankle joints of arthritic mice for mice treated with anti-GM-CSF or control mAb every second day from days 21 to 31 post immunization. Results are expressed as the mean level ± SEM (pg/ml). *P = 0.02 and **P = 0.007 compared with control mAb-treated mice. GM-CSF, Granulocyte macrophage-colony stimulating factor; IL-1β, interleukin-1β; mAb, monoclonal antibody; TNFα, tumor necrosis factor-α. Cytokine level (pg/ml) At sites of inflammation, including joints, GM-CSF has been proposed to form part of an inflammatory cytokinedriven feedback cascade termed the 'CSF network' [26] [27] [28] [29] [30] . Our predictions from this model are that exogenous GM-CSF will potentiate inflammatory disease and that it will be a therapeutic target -there is now evidence for both these hypotheses. By blocking GM-CSF, fewer primed macrophages (and granulocytes) would thus be present at a site of inflammation, as evidenced by the current study, with the result that less mediators would be produced to promote inflammation and tissue destruction.
Conclusion
Experimental data indicating suppression of CIA by anti-TNFα antibody treatment preceded successful TNFα targeting in RA [12, 31] . The present data show that anti-GM-CSF mAb treatment also suppresses CIA and, in particular, that existing disease can be ameliorated. These results suggest that the major effect of GM-CSF in CIA is in mediating the effector phase of the inflammatory reaction to CII. Both the inflammatory and erosive processes are affected, and the levels of key proinflammatory cytokines in RA, TNFα and IL-1β, are reduced, suggesting that consideration be likewise given to modulating GM-CSF clinically for inflammatory conditions. 
Supplementary material Materials and methods
Collagen-induced arthritis
Male DBA/1 mice, 8-12 weeks old (ARC, Canning Vale, WA, USA) were immunized intradermally in the base of the tail with 100 µg chick CII (Sigma, St. Louis, MO, USA) emulsified in an equal volume of complete Freund's adjuvant containing 5 mg/ml heat-killed Mycobacterium tuberculosis (H37 Ra; Difco, Detroit, MI, USA). This procedure was repeated as a boost 21 days later, as previously published [8] [9] [10] [11] .
mAb treatment
Mice were treated i.p. with 300 µg of the appropriate mAb in a volume of 100 µl at various times. The first treatment was prior to the clinical onset of arthritis at the time of primary immunization (day 0), either once or at weekly intervals from days 0 to 21. Another treatment occurred at the time of antigen challenge (day 21), either once, twice (days 21 and 23), or every second day from days 21 to 31. For the latter regime, 30 and 100 µg anti-GM-CSF mAb were also used. The final time for treatment was following clinical onset of arthritis. For treatment of existing arthritis, mAb was administered daily for a total of 10 days following onset of arthritis. Mice were paired according to their arthritic score and then assigned to either the anti-GM-CSF mAb treatment group or the isotype control mAb treatment group, such that both groups had approximately the same clinical score (mean ± SEM) on the first day of mAb administration (day 0).
T-cell proliferation assay
Cells from inguinal lymph nodes were isolated from mice treated every second day with 300 µg of mAb from days 21 to 31. These cells were cultured (5 × 10 5 cells/well, 2-3 mice/group), for 72 hours at 37°C (5% CO 2 ), with 0-100 µg/ml denatured CII (boiled for 10 min) in RPMI containing 50 µM 2-ME and 5% (v/v) fetal calf serum (200 µl/well) [10] . Either anti-GM-CSF mAb or isotypecontrol mAb were added to selected wells at concentrations of 100 µg/ml. 
Cytokine ELISAs
The coating and capture antibodies, respectively, used in the cytokine ELISAs were anti-GM-CSF mAb (22E9.11; DNAX [13] ) and a biotinylated anti-GM-CSF mAb (31G6.41; Pharmingen, San Diego, CA, USA) for GM-CSF; anti-TNFα mAb (G281-2626; Pharmingen) and a biotinylated anti-TNFα mAb (MP6-XT3; Pharmingen) for TNFα; and polyclonal anti-IL-1β Ab and a biotinylated anti-IL-1β mAb (Endogen, Woburn, MA, USA) for IL-1β. A streptavidin-horseradish peroxidase conjugate (Pharmingen) followed by TMB-peroxidase substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) was used to detect the cytokines. A standard curve was constructed using serial dilutions of purified GM-CSF, TNFα, or IL-1β starting at a concentration of 2 ng/ml. Each ELISA was sensitive down to 15 pg/ml.
Results
GM-CSF blockade prior to onset of arthritis results in less severe disease
Mice treated i.p. with 300 µg anti-GM-CSF beginning at day 21 and then every second day until day 31 showed a decrease in disease severity. The decrease in severity was seen both as a reduction in the number of affected limbs per mouse (Supplementary Fig. 1a ) and lower clinical scores for these affected limbs ( Supplementary Fig. 1b) . For example, only 1 of 9 (11%) anti-GM-CSF-treated mice had more than one limb affected compared with 8 of 10 (80%) isotype control-treated mice (P = 0.003) (Supplementary Fig. 1a) . Also, none of the affected limbs from anti-GM-CSF mAb-treated mice had a clinical score of 3 (maximum) compared with 19 individual limbs from isotype control-treated mice ( Supplementary Fig. 1b ).
Because continued treatment with anti-GM-CSF was effective in modifying the disease when initiated at antigen challenge (i.e. day 21 after primary immunization), the effect of the addition of anti-GM-CSF mAb at different times prior to disease onset was examined. Treatment with anti-GM-CSF mAb on days 21 and 23 resulted in a slight suppression of the clinical score that was significant on day 40 (P = 0.044) (Supplementary Fig. 2a ). There was, however, no significant difference in the incidence, day of onset, or the number of limbs affected per mouse compared with isotype control-treated mice (data not shown). Treatment with anti-GM-CSF mAb on day 21 only did not result in any significant differences compared with isotype control-treated mice, although there was a trend towards slightly lower mean clinical scores ( Supplementary Fig. 2a ).
To assess the effectiveness of treatment with anti-GM-CSF mAb during the primary induction phase of disease, mice were treated i.p. with a single injection of 300 µg anti-GM-CSF mAb at the time of immunization (day 0) (Supplementary Fig. 2b ), or at weekly intervals from the time of immunization until day 21 (Supplementary Fig. 2c ). There were no significant differences in the mean clinical scores ( Supplementary Fig. 2b,c) , the incidence or the day of onset (data not shown) between mice treated with anti-GM-CSF mAb and control mAb for either treatment regime. Mice treated weekly with anti-GM-CSF mAb up to and including day 21 showed a trend towards slightly lower mean clinical scores ( Supplementary Fig. 2c) ; findings similar to mice treated on day 21 (Supplementary Fig. 2a ).
GM-CSF blockade prevents the clinical progression of established arthritis
To further examine the suppression of disease seen in anti-GM-CSF mAb-treated mice with established disease, the progression of arthritis in initially affected limbs (Supplementary Fig. 3a ) and the recruitment of additional limbs and their severity, analyzed individually ( Supplementary  Fig. 3b ), were compared between the anti-GM-CSF mAbtreated and isotype control-treated groups. The absence of disease progression was seen as a relative lack of increase in the clinical score of initially affected limbs ( Supplementary Fig. 3a ). For example, the clinical score of 23 of the 33 (70%) initially affected limbs from the anti-GM-CSF mAb-treated group either did not change or improved (i.e. a lower score) following treatment, compared with only 9 of the 31 (29%) initially affected limbs from the control-treated group (P = 0.001). Furthermore, there was a diminished recruitment of additional limbs during treatment ( Supplementary Fig. 3b ). Of note, only 8 of 47 (17%) limbs that were normal at the commencement of treatment from the anti-GM-CSF-treated group developed arthritis compared with 23 of 45 (51%) limbs that were normal from the isotype control-treated group (P = 0.001). The arthritis that developed in limbs after the commencement of treatment with anti-GM-CSF mAb was very mild with a clinical score of only 1 in all cases. The arthritis that developed in limbs after the commencement of treatment with the control mAb, however, ranged from mild (clinical score of 1) to severe (clinical score of 3) (Supplementary Fig. 3b ).
Reduced histopathology of joints following GM-CSF blockade
The cellular infiltration and degree of joint erosion were quantified from randomly selected mice from each treatment group; 124 joints from 18 hind limbs of anti-GM-CSF-treated mice and 142 joints from 16 hind limbs of control-treated mice were examined by microscopy. There was a significant correlation between the clinical score of each limb and each histologic feature for both treatment groups (data not shown).
Humoral and cellular response to CII following GM-CSF blockade in vivo
Antibodies to CII were measured in serum at the end of each experiment. Treatment with anti-GM-CSF mAb either post-onset or at various times prior to onset (days 21-31, day 0, or weekly from days 0 to 21) had no effect on the anti-CII IgG response (Supplementary Fig. 4a ).
CII-specific T-cell expansion was measured in vitro from mice treated with mAb every second day from days 21 to 31. There was no difference in the proliferative response of T cells to CII from anti-GM-CSF mAb-treated mice compared with control mAb-treated mice ( Supplementary  Fig. 4b ). Furthermore, in vitro treatment with anti-GM-CSF mAb also had no effect on the CII-specific proliferative response (Supplementary Fig. 4c ). 
